The pathobiological harmony between the local pulmonary/ bone marrow RAS and its management via tissue-RAS modulating agents in COVID-19

Basit Öğe Kaydı
dc.contributor.authorÇetin, Ece Ünal
dc.contributor.authorBeyazıt, Yavuz
dc.contributor.authorBeyazıt, Fatma
dc.contributor.authorTanoğlu, Alpaslan
dc.contributor.authorHaznedaroğlu, İbrahim Celaleddin
dc.date.accessioned2025-05-29T05:24:51Z
dc.date.available2025-05-29T05:24:51Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractCoronavirus disease 2019 (COVID-19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an unprecedented threat to public health and healthcare systems. It presents unusual pathophysiological effects mainly characterized by immune-inflammatory response and prothrombotic state causing acute respiratory distress syndrome and multiple organ failure. SARS-CoV-2 enters target cells after binding to the angiotensin-converting enzyme 2 (ACE2) receptor and therefore has a direct effect on the renin-angiotensin system (RAS). Apart from affecting numerous organs including lungs, heart, gastrointestinal system, spleen, brain and kidneys, the spike protein of SARS-CoV-2 could attack hematopoietic stem cells and hematopoietic progenitor cells in bone marrow (BM) microenvironment together with the precursor and mature blood cells. Within this hematopoietic viral spread context, it is crucial to search the clinicopathological correlations of COVID-19 in order to develop specific potential therapeutics against pleiotropic SARS-CoV-2 actions. Therefore, pharmacological disruption of the pathological cross-talk of local BM RAS and pulmonary RAS via administration of the tissue-RAS modulating agents such as soluble ACE2, angiotensin (1-7), TXA127 and MAS receptor agonists may prevent the clinical progression of the COVID-19 syndrome via reducing the hematopoietic virus propagation and systemic multi-organ spread.
dc.identifier.doi10.32322/jhsm.1090521
dc.identifier.endpage937
dc.identifier.issn2636-8579
dc.identifier.issue3
dc.identifier.startpage932
dc.identifier.urihttps://doi.org/10.32322/jhsm.1090521
dc.identifier.urihttps://hdl.handle.net/20.500.12428/31028
dc.identifier.volume5
dc.language.isoen
dc.publisherMediHealth Academy Yayıncılık
dc.relation.ispartofJournal of Health Sciences and Medicine
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_DergiPark_20250529
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectACE2
dc.subjectrenin-angiotensin system
dc.subjectbone marrow
dc.titleThe pathobiological harmony between the local pulmonary/ bone marrow RAS and its management via tissue-RAS modulating agents in COVID-19
dc.typeReview

Dosyalar

Koleksiyon

DergiPark